Association between delay in intensive care unit admission and the host response in patients with community-acquired pneumonia.
Delayed admission
Host immune response
Intensive care unit
Pneumonia
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
28 Sep 2021
28 Sep 2021
Historique:
received:
01
07
2021
accepted:
20
09
2021
entrez:
29
9
2021
pubmed:
30
9
2021
medline:
30
9
2021
Statut:
epublish
Résumé
A delay in admission to the intensive care unit (ICU) of patients with community-acquired pneumonia (CAP) has been associated with an increased mortality. Decisions regarding interventions and eligibility for immune modulatory therapy are often made at the time of admission to the ICU. The primary aim of this study was to compare the host immune response measured upon ICU admission in CAP patients admitted immediately from the emergency department (direct ICU admission) with those who were transferred within 72 h after admission to the general ward (delayed ICU admission). Sixteen host response biomarkers providing insight in pathophysiological mechanisms implicated in sepsis and blood leukocyte transcriptomes were analysed in patients with CAP upon ICU admission in two tertiary hospitals in the Netherlands. Of 530 ICU admissions with CAP, 387 (73.0%) were directly admitted and 143 (27.0%) had a delayed admission. Patients with a delayed ICU admission were more often immunocompromised (35.0 versus 21.2%, P = .002) and had more malignancies (23.1 versus 13.4%, P = .011). Shock was more present in patients who were admitted to the ICU directly (46.6 versus 33.6%, P = .010). Delayed ICU admission was not associated with an increased hospital mortality risk (hazard ratio 1.25, 95% CI 0.89-1.78, P = .20). The plasma levels of biomarkers (n = 297) reflecting systemic inflammation, endothelial cell activation and coagulation activation were largely similar between groups, with exception of C-reactive protein, soluble intercellular adhesion molecule-1 and angiopoietin-1, which were more aberrant in delayed admissions compared to direct ICU admissions. Blood leukocyte transcriptomes (n = 132) of patients with a delayed ICU admission showed blunted innate and adaptive immune response signalling when compared with direct ICU admissions, as well as decreased gene expression associated with tissue repair and extracellular matrix remodelling pathways. Blood leukocytes of CAP patients with delayed ICU admission show evidence of a more immune suppressive phenotype upon ICU admission when compared with blood leukocytes from patients directly transferred to the ICU. Molecular Diagnosis and Risk Stratification of Sepsis (MARS) project, ClinicalTrials.gov identifier NCT01905033.
Sections du résumé
BACKGROUND
BACKGROUND
A delay in admission to the intensive care unit (ICU) of patients with community-acquired pneumonia (CAP) has been associated with an increased mortality. Decisions regarding interventions and eligibility for immune modulatory therapy are often made at the time of admission to the ICU. The primary aim of this study was to compare the host immune response measured upon ICU admission in CAP patients admitted immediately from the emergency department (direct ICU admission) with those who were transferred within 72 h after admission to the general ward (delayed ICU admission).
METHODS
METHODS
Sixteen host response biomarkers providing insight in pathophysiological mechanisms implicated in sepsis and blood leukocyte transcriptomes were analysed in patients with CAP upon ICU admission in two tertiary hospitals in the Netherlands.
RESULTS
RESULTS
Of 530 ICU admissions with CAP, 387 (73.0%) were directly admitted and 143 (27.0%) had a delayed admission. Patients with a delayed ICU admission were more often immunocompromised (35.0 versus 21.2%, P = .002) and had more malignancies (23.1 versus 13.4%, P = .011). Shock was more present in patients who were admitted to the ICU directly (46.6 versus 33.6%, P = .010). Delayed ICU admission was not associated with an increased hospital mortality risk (hazard ratio 1.25, 95% CI 0.89-1.78, P = .20). The plasma levels of biomarkers (n = 297) reflecting systemic inflammation, endothelial cell activation and coagulation activation were largely similar between groups, with exception of C-reactive protein, soluble intercellular adhesion molecule-1 and angiopoietin-1, which were more aberrant in delayed admissions compared to direct ICU admissions. Blood leukocyte transcriptomes (n = 132) of patients with a delayed ICU admission showed blunted innate and adaptive immune response signalling when compared with direct ICU admissions, as well as decreased gene expression associated with tissue repair and extracellular matrix remodelling pathways.
CONCLUSIONS
CONCLUSIONS
Blood leukocytes of CAP patients with delayed ICU admission show evidence of a more immune suppressive phenotype upon ICU admission when compared with blood leukocytes from patients directly transferred to the ICU.
TRIAL REGISTRATION
BACKGROUND
Molecular Diagnosis and Risk Stratification of Sepsis (MARS) project, ClinicalTrials.gov identifier NCT01905033.
Identifiants
pubmed: 34585271
doi: 10.1186/s13613-021-00930-5
pii: 10.1186/s13613-021-00930-5
pmc: PMC8478267
doi:
Banques de données
ClinicalTrials.gov
['NCT01905033']
Types de publication
Journal Article
Langues
eng
Pagination
142Subventions
Organisme : center for translational molecular medicine
ID : 04I-201
Organisme : ZonMw
ID : 547001008
Pays : Netherlands
Organisme : nierstichting
ID : Kolff Grant 19OK009
Informations de copyright
© 2021. The Author(s).
Références
Ann Intensive Care. 2018 Aug 15;8(1):84
pubmed: 30112650
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Nat Rev Nephrol. 2020 Jan;16(1):20-31
pubmed: 31511662
Proc Natl Acad Sci U S A. 2010 May 25;107(21):9546-51
pubmed: 20460310
Expert Rev Anti Infect Ther. 2011 Nov;9(11):1013-33
pubmed: 22029521
PLoS One. 2016 Jan 04;11(1):e0145929
pubmed: 26727202
Crit Care. 2006;10(6):237
pubmed: 17118216
Am J Respir Crit Care Med. 2016 Dec 1;194(11):1366-1374
pubmed: 27267747
JAMA. 2016 Apr 12;315(14):1469-79
pubmed: 26975785
Crit Care Med. 2013 Oct;41(10):2373-8
pubmed: 23921277
PLoS Genet. 2007 Sep;3(9):1724-35
pubmed: 17907809
Am J Respir Crit Care Med. 2011 Jun 1;183(11):1561-8
pubmed: 21297074
Am J Respir Cell Mol Biol. 2014 Apr;50(4):699-712
pubmed: 24164497
Chest. 2010 Mar;137(3):552-7
pubmed: 19880910
Thorax. 2004 May;59(5):421-7
pubmed: 15115872
N Engl J Med. 2015 Jul 30;373(5):415-27
pubmed: 26172429
J Leukoc Biol. 2020 Sep;108(3):787-799
pubmed: 32182390
Eur Respir J. 2010 Oct;36(4):826-33
pubmed: 20185424
Bioinformatics. 2004 Feb 12;20(3):307-15
pubmed: 14960456
Crit Care Med. 2012 Jul;40(7):2041-9
pubmed: 22713216
Biomed Res Int. 2018 Jun 19;2018:6057589
pubmed: 30018981
Clin Chim Acta. 2016 Dec 1;463:174-180
pubmed: 27983998
Am J Respir Crit Care Med. 2018 Aug 1;198(3):370-378
pubmed: 29509439
Crit Care Med. 2011 Apr;39(4):702-10
pubmed: 21242795
Arch Intern Med. 2012 Mar 26;172(6):467-74
pubmed: 22412076
N Engl J Med. 2013 Nov 21;369(21):2063
pubmed: 24256390
Nat Rev Dis Primers. 2021 Apr 8;7(1):25
pubmed: 33833230
Nat Rev Immunol. 2017 Jul;17(7):407-420
pubmed: 28436424
Crit Care Med. 2014 Jul;42(7):1714-21
pubmed: 24717456
Physiol Rev. 2018 Jul 1;98(3):1417-1464
pubmed: 29767563
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Nat Rev Nephrol. 2018 Feb;14(2):121-137
pubmed: 29225343
Crit Care Med. 2009 Nov;37(11):2867-74
pubmed: 19770748
Adv Emerg Nurs J. 2012 Apr-Jun;34(2):164-9
pubmed: 22561226
Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):818-24
pubmed: 7509706
Am J Respir Cell Mol Biol. 2012 Oct;47(4):395-404
pubmed: 22652197
Crit Care. 2011;15(1):R28
pubmed: 21244671
Clin Transl Immunology. 2020 Jul 06;9(7):e1152
pubmed: 32665845
Intensive Care Med. 2019 Feb;45(2):159-171
pubmed: 30706119
BMJ Open. 2014 Nov 27;4(11):e005553
pubmed: 25431221
Curr Opin Crit Care. 2018 Dec;24(6):531-539
pubmed: 30239410
Crit Care. 2004 Aug;8(4):R204-12
pubmed: 15312219
Thromb Res. 2018 Nov;171:149-154
pubmed: 30312800
Crit Care Med. 2007 Jun;35(6):1477-83
pubmed: 17440421
Crit Care Med. 2018 Jul;46(7):e692-e701
pubmed: 29649066